CNBC · General

Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market

· By Evelyn Cheng
Story summary

BEIJING — U.S. pharmaceutical giant Eli Lilly has reached a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market.

Read at CNBC

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.

Your local edition.

Choose a timezone for story timestamps and date filters.